ArticleCureus2025
Use of N-hexyl Cyanoacrylate Monomers for the Treatment of Intra- and Extracranial Arteriovenous Malformations: A Single-Center Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CIRSE Standards of Practice for the Use of Non-sclerosant Liquid Embolic Agents in IR Practice.Cardiovascular and interventional radiology · 2026Article
- Letter to the Editor: The safety and effectiveness of ethanol embolosclerotherapy in the treatment of arterio-venous malformations: a systematic review and meta-analysis.European radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLiquid embolic agents (LEAs) are commonly used in the endovascular treatment of vascular malformations for their penetration, visibility, and reflux control. This study presents our experience with N-hexyl cyanoacrylate (NHCA), also known as "Magic Glue," and its strengths and limitations.
methodsA retrospective single-center case series study was conducted to assess outcomes among patients with complex head and neck vascular lesions treated with NHCA injection at Hospital Universitario Central de Asturias, Oviedo, Spain, between January 2022 and December 2023. Procedure and outcome measures included justification for using NHCA, technical success (defined as the outcome achieved based on objective), materials used for catheterization, dilution ratio of NHCA, and observations of technical significance during the procedure.
resultsA total of 24 NHCA injections were performed in 22 patients with intra- and extracranial vascular lesions. An arteriovenous malformation (AVM) was treated in 83.3% (20/24) of cases, including nidal pseudoaneurysms in ruptured AVMs (8/24, 33.3%), arterial feeder embolization in AVM treatment (7/24, 29.2%), and single-feeder AVMs (5/24, 20.8%). The remaining cases included bone or skin vascular malformations (2/24, 8.3%) and dural arteriovenous fistulas (2/24, 8.3%). In 87.5% (21/24) of cases, procedures were successful using a 1:4 dilution ratio of NHCA in lipiodol. In 70.8% (17/24) of cases, the HeadWay Duo 167 cm microcatheter was used to gain arterial access, and the Magic 1.2F 165 cm microcatheter was used in the remaining cases. Injection durations ranged from 27 seconds to 9 minutes and 38 seconds. No clinically significant complications occurred, and microcatheter retrieval was successful in 100% of cases. Complete occlusion with a single NHCA injection into the arterial feeder was achieved in 12.5% (3/24) of cases. NHCA demonstrated optimal penetration and advancement capacity in both intranidal and proximal injections, allowing effective embolization of complex vascular structures.
conclusionNHCA demonstrated safe and effective penetration and advancement in both intranidal and proximal injections, allowing successful embolization of complex vascular structures. Further research is necessary to establish its long-term efficacy and optimize its clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.